Unknown

Dataset Information

0

Integrating Genetic Alterations and the Hippo Pathway in Head and Neck Squamous Cell Carcinoma for Future Precision Medicine.


ABSTRACT: Genetic alterations and dysregulation of signaling pathways are indispensable for the initiation and progression of cancer. Understanding the genetic, molecular, and signaling diversities in cancer patients has driven a dynamic change in cancer therapy. Patients can select a suitable molecularly targeted therapy or immune checkpoint inhibitor based on the driver gene alterations determined by sequencing of cancer tissue. This "precision medicine" approach requires detailed elucidation of the mechanisms connecting genetic alterations of driver genes and aberrant downstream signaling pathways. The regulatory mechanisms of the Hippo pathway and Yes-associated protein/transcriptional co-activator with PDZ binding motif (YAP/TAZ) that have central roles in cancer cell proliferation are not fully understood, reflecting their recent discovery. Nevertheless, emerging evidence has shown that various genetic alterations dysregulate the Hippo pathway and hyperactivate YAP/TAZ in cancers, including head and neck squamous cell carcinoma (HNSCC). Here, we summarize the latest evidence linking genetic alterations and the Hippo pathway in HNSCC, with the aim of contributing to the continued development of precision medicine.

SUBMITTER: Ando T 

PROVIDER: S-EPMC9604790 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Integrating Genetic Alterations and the Hippo Pathway in Head and Neck Squamous Cell Carcinoma for Future Precision Medicine.

Ando Toshinori T   Okamoto Kento K   Shintani Tomoaki T   Yanamoto Souichi S   Miyauchi Mutsumi M   Gutkind J Silvio JS   Kajiya Mikihito M  

Journal of personalized medicine 20220920 10


Genetic alterations and dysregulation of signaling pathways are indispensable for the initiation and progression of cancer. Understanding the genetic, molecular, and signaling diversities in cancer patients has driven a dynamic change in cancer therapy. Patients can select a suitable molecularly targeted therapy or immune checkpoint inhibitor based on the driver gene alterations determined by sequencing of cancer tissue. This "precision medicine" approach requires detailed elucidation of the mec  ...[more]

Similar Datasets

| S-EPMC6947155 | biostudies-literature
| S-EPMC5655563 | biostudies-literature
| S-EPMC7289307 | biostudies-literature
| S-EPMC9243320 | biostudies-literature
| S-EPMC5989049 | biostudies-other
| S-EPMC3184846 | biostudies-literature
| S-EPMC9224778 | biostudies-literature
| S-EPMC4905189 | biostudies-other
| S-EPMC7947611 | biostudies-literature
| S-EPMC8927572 | biostudies-literature